Researcher

Title

• Professor assistant pediatric nephrology Sainte Justine hospital

Laboratory

Les Néphrontées

• 2020 –2021.  Post Doctoral training Université de Paris, Paris, France ; Centre de recherche sur l'inflammation (CRI) ; INSERM U1149; CNRS ERL8252 ; Inflamex Laboratory of Excellence, Paris, France 
• 2017 – 2020. Science PhD « Physiologie, Physiopathologie et thérapeutique, Paris Diderot ».  « Études des marqueurs immuns et des facteurs génétiques dans la néphropathie à IgA de l’enfant. » PhD directors : Pr Renato Monteiro INSERM UMR1149 et Dr Laurent Mesnard Unité recherche INSERM UMR S 1155
• 2019 – 2020. Hospital practician nomination
• 2018 – 2020. European master of pediatric nephrology degree (IPNA ESPN Master)
• 2017– 2018. Doctor of medicine in pediatrics (MD)
• 2015 – 2016. French university pediatric nephrology degree                                         
• 2013 – 2014. Master’s degree in advance immunology. Pasteur Institut (Paris) and University of California in San Francisco (UCSF)
• 2012 – 2013. Pediatric Residency admission in Paris

• Pathophysiology childhood IgA nephropathy
• Biomarker’s childhood IgA nephropathy
• Genetic predisposition childhood IgA nephropathy
• Specific treatment childhood IgA nephropathy

• Pediatrics
• Nephrology
• Immunology
• Complement pathway
• IgA nephropathy
• CD89
• Gd-IgA

Career Summary

I completed my pediatric medicine and nephrology training at the University of Paris in 2018. I subsequently did a three-years pediatric nephrology fellowship at the Robert Debré Hospital in Paris. I then did a PHD in immunology at the faculty of the Bichat Hospital, in the Inflamex Laboratory of Excellence with Pr. Renato Monteiro. I have completed my PHD working in genetics with Pr. Laurent Mesnard at Sorbonne University Laboratory UMR_S 1155. My research focuses on childhood IgA nephropathy and my research interests encompass the clinical specificities of childhood IgA nephropathy as well as the interest of immune biomarkers for diagnosis and prognosis of disease and the impact of genetic variants.

Awards and Distinctions

Financing

• Support program for clinical researchers from Montreal univeristy
• Research subvention from Nephrology Consortium, Montreal University 
• ORKID fundings 2022: “mTOR inhibitors blocking CD89 in IgA nephropathy proliferation”
• Lauréat Fundings AIRG 2016 : whole exome sequencing for children IgA nephropathy « De la néphropathie à IgA de l’enfant : Implications physiopathologiques et thérapeutiques »

Presentations

• 23/09/2021. Invited speaker. IIGANN (International Symposium on IgANephropathy) Prague (Is there a link between collagen IV mutations and IgAN?)
• 16/09/2021. ESPN (European society pediatric nephrology) Amsterdam (Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA Nephropathy)
• 18/10/2019. IPNA (International Pediatric nephrology Association) Venise (Biomarkers of children IgA nephropathy)
• 04/07/2019. Invited speaker at Robert Debré Hospital. Chronic renal failure and IgA nephropathy.
• 01/11/2019. SNP (Société Néphrologie pédiatrique) Lille (Clinical and histological differences between adults and children in new onset IgA nephropathy)

Publications

• Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification. Alexandra Cambier, Stéphan Troyanov, Vladimir Tesar, Rosanna Coppo,for the Validation Study of Oxford Classification (VALIGA) Group. Nephrology Dialysis Transplantation. Feb 02, 2022. https://doi.org/10.1093/ndt/gfac025
• Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy. Cambier A, Gleeson PJ, Abbad L, Canesi F, da Silva J, Bex-Coudrat J, Deschênes G, Boyer O, Rabant M, Ulinski T, Hogan J, Peuchmaur M, Berthelot L, Monteiro RC.Kidney Int. 2021 Oct 28:S0085-2538(21)00954-6. doi: 10.1016/j.kint.2021.09.023. Online ahead of print.PMID: 34756952
• Specific immune biomarker monitoring in two children with severe IgA nephropathy and successful therapy with immunoadsorption in a rapidly progressive case Cambier A, Dossier C, Hogan J, Baudouin V, Maisin A, Couderc A, Kwon T, Gleeson PJ, Monteiro R. Pediatr Nephrol. 2020. PMID : 34997322
• Rare Collagenous Heterozygote Variants in Children With IgA Nephropathy. Cambier A, Robert T, Hogan J, Rabant M, Peuchmaur M, Boyer O, Ulinski T, Monteiro RC, Mesnard L.Kidney Int Rep. 2021 Mar 3;6(5):1326-1335. doi: 10.1016/j.ekir.2021.02.022. eCollection 2021 May.PMID: 34013111 
• Clinical and histological differences between adults and children in new onset IgA nephropathy. Cambier A, Rabant M, El Karoui K, Peuchmaur M, Servais A, Hertig A, Deschenes G, Salomon R, Hogan J, Robert T.Pediatr Nephrol. 2020 Oct;35(10):1897-1905. doi: 10.1007/s00467-020-04614-3. Epub 2020 May 22.PMID: 32444925
• New therapeutic perspectives for IgA nephropathy in children. Cambier A, Gleeson PJ, Flament H, Le Stang MB, Monteiro RC.Pediatr Nephrol. 2021 Mar;36(3):497-506. doi: 10.1007/s00467-020-04475-w. Epub 2020 Feb 10.PMID: 32040630 Review.
• Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features. Cambier A, Rabant M, Peuchmaur M, Hertig A, Deschenes G, Couchoud C, Kolko A, Salomon R, Hogan J, Robert T.Kidney Int Rep. 2018 Mar 29;3(4):916-925. doi: 10.1016/j.ekir.2018.03.013. eCollection 2018 Jul.PMID: 29988999